TNF inhibitors, including etanercept, adalimumab, infliximab, and golimumab, are used in several autoinflammatory disorders, including the IEI deficiency of adenosine deaminase 2 (DADA2), in which cytopenias, either autoimmune or due to bone marrow failure (BMF), occur in 50% of patients. This evidence concerns the gene TNF and Bone marrow hypocellularity.